Physician profile
Robert Mannel
NPI 1093073181
$92,130.86
in general payments reported to CMS, 2019-2025
51 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $161 · 2021: $188 · 2022: $1,880 · 2023: $3,885 · 2024: $44K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $12K · Travel and Lodging: $3,951 · Consulting Fee: $3,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,397.00 |
| Food and Beverage | $11,918.08 |
| Travel and Lodging | $3,950.92 |
| Consulting Fee | $3,325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $57,906.63 | 2023-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $20,070.22 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,600.78 | 2019-2025 | |
| Onmark, INC. | $1,400.00 | 2024 | |
| Lundbeck LLC | $1,083.08 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $986.87 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $947.09 | 2023-2025 | |
| Biogen, INC. | $697.96 | 2020-2025 | Tysabri, Leqembi, Vumerity |
| Sk Life Science, INC. | $635.06 | 2022-2025 | Xcopri |
| Pfizer INC. | $489.19 | 2023-2025 | |
| Argenx US, INC. | $420.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Corium, LLC | $401.41 | 2022-2023 | Adlarity |
| Acadia Pharmaceuticals INC | $347.79 | 2023-2025 | Nuplazid |
| Emd Serono, INC. | $309.05 | 2023-2025 | Mavenclad |
| Amgen INC. | $295.50 | 2022-2025 | Uplizna |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mannel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.